Navigation Links
New chemotherapy combo produces side effects, but no extra efficacy, in early breast cancer patients
Date:4/17/2008

Berlin, Germany: Adding capecitabine, a drug that inhibits DNA synthesis and slows the growth of tumour tissue, to docetaxel, in patients with early breast cancer, leads to more toxicities and does not improve the efficacy of treatment, a German scientist told the 6th European Breast Cancer Conference (EBCC-6) today (Thursday 17 April). Previously, such a combination had improved patient survival in metastatic disease, where the cancer has spread to other parts of the body.

Professor Gunter von Minckwitz, Chairman of the German Breast Group, Neu-Isenberg, Germany, and his team set out to look at the use of the combination in early breast cancer. We recruited 1510 patients with previously untreated primary tumours, he said. Each received the normal preoperative treatment of four cycles of epirubicin and cyclophosphamide. We then randomised them to either four cycles of docetaxel alone, four cycles of simultaneous docetaxel and capecitabine, or four cycles of docetaxel followed by four cycles of capecitabine. If capecitabine were to improve outcomes, we wanted to see how best to use it simultaneously or in sequence.

The scientists planned to study the pathologic response at surgery the way, if any, in which the tumour had reacted to the administration of the chemotherapy drug.

However, we found no difference in efficacy between the three arms of the trial with regard to pathologic response, clinical response, and rate of breast conservations, said Professor von Minckwitz. The overall rate of pathologic complete responses (pCRs) no cancer in the breast or lymph nodes was 29.7%.

Nor did the length of treatment appear to make a statistically significant difference. What the scientists did find was that the addition of capecitabine to the chemotherapy regime produced more non-haematological toxicities for example hand-foot syndrome, a skin reaction that appears on the palms of the hands and soles of the feet, and
'/>"/>

Contact: Mary Rice
mary@mrcommunication.org
ECCO-the European CanCer Organisation
Source:Eurekalert

Page: 1 2

Related biology news :

1. A search for protection against chemotherapy cardiotoxicity
2. UC health news: molecular pathway may predict chemotherapy effectiveness
3. Insecticide combo delivers knockout punch
4. Cigarette smoke, alcohol damage hearts worse as combo
5. New study shows Dermytol produces pronounced decrease in malignant melanoma tumor volume
6. Extract of broccoli sprouts may protect against bladder cancer
7. A compound extracted from olives inhibits cancer cells growth and prevents their appearance
8. Videos extract mechanical properties of liquid-gel interfaces
9. 4 health behaviors can add 14 extra years of life
10. Bilberry extract -- can it help prevent certain cancers?
11. Research team says extraterrestrial impact to blame for Ice Age extinctions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... losing weight is enough to prevent Type 2 diabetes, don,t ... 2014 issue of The FASEB Journal , ... Type 2 diabetes. This study compared genetically identical twins-one heavier ... the circulating metabolites, including those related to Type 2 diabetes, ... These findings suggest that the onset of this type of ...
(Date:9/2/2014)... birds, also known as perching birds, that migrate by ... do in autumn to reach their destinations. This seasonal ... that only make short migratory flights, says researcher Cecilia ... Behavioral Ecology and Sociobiology . , Nilsson, ... a tracking radar to measure over three years the ...
(Date:9/2/2014)... the last decade in Taiyuan, China, have substantially improved ... greater than 50% reduction in costs associated with loss ... to researchers at the Columbia Center for Children,s Environmental ... the Shanxi Medical University, the Center of Diseases Control ... School of Public Health. , The study is the ...
Breaking Biology News(10 mins):What you eat and not just the number of calories, is a significant factor in diabetes risk 2Migrating birds sprint in spring, but take things easy in autumn 2Clean air halves health costs in Chinese city 2
... at least 20 percent of adults in the United ... that prevents bones from rubbing together. By studying the ... how the earliest stages of arthritis make the tissue ... running or jumping. The findings could help researchers ...
... ARBOR, Mich. For nearly two years, University of Michigan ... clinical trial of stem cell injections in patients with the ... ALS or Lou Gehrig,s disease. Now, a new ... way for U-M to become the second site in the ...
... sometimes called "hardening of the arteries" is ... countries. A cell-permeable peptide containing the NF-ĸB nuclear localization ... controlling the development of atherosclerotic disease. This study is ... American Journal of Pathology . Atherosclerosis is a ...
Cached Biology News:Hop, skip or jump? Study says no to all of the above 2Hop, skip or jump? Study says no to all of the above 3FDA approves Phase II of stem cell trial for ALS led by U-M's Dr. Eva Feldman 2Cell-permeable peptide shows promise for controlling cardiovascular disease 2
(Date:9/2/2014)... NEW YORK , September 2, 2014 ... Market Study on Membrane Technology in Pharmaceutical, Biopharma and ... Witness Highest Growth by 2019" the global membrane technology market for ... 7,029.9 million in 2014 and is expected to grow ... to reach an estimated value of USD 10,886.0 million ...
(Date:9/2/2014)... Opertech Bio, Inc., a company that ... approach to sensory evaluation, today announced the issuance ... Patent and Trademark Office, encompassing high-throughput sensory discrimination ... taste evaluation technology called Microtiter Operant Gustometer or ... for rapid characterization of taste sensory properties,” said ...
(Date:9/2/2014)... 2014  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... candidates targeting specific pathogens that cause serious infections ... final preclinical toxicology study of SYN-004. Per U.S. ... study was required to move the Company,s lead ... devastating effects of Clostridium difficile (C. difficile), ...
(Date:9/2/2014)... September 2, 2014 Culot brings ... and lab management services  BioData, producer of ... pleased to announce the appointment of Louis Culot ... served as VP Marketing and Business Development at BioDiscovery ... and clinical applications. Previously, Culot worked for ...
Breaking Biology Technology:Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 3Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 4Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 5Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5Louis Culot Appointed as BioData's CEO 2
... The Muscular Dystrophy Association announced today that it ... biotechnology company, to develop and test a "dissociative glucocorticoid" ... (DMD) . (Logo: http://photos.prnewswire.com/prnh/20120424/DC93207LOGO ) ... Institutes of Health Therapeutics for Rare and Neglected Diseases ...
... May 3, 2012 ZyGEM Corp. Ltd., a developer ... DNA and other nucleic acids, today announced it has ... distribution of ZyGEM,s DNA and RNA extraction products in ... a leading provider of quantitative real-time PCR (qPCR) services ...
... SEATTLE, May 3, 2012 CMC Biologics, a leading ... technical excellence in process development and cGMP manufacture ... Manufacturing Company of the Year – Large Category.   The ... partnership with Impact Washington, brought together nearly 300 leaders ...
Cached Biology Technology:MDA Supports Development of 'Dissociative Glucocorticoid' for DMD 2MDA Supports Development of 'Dissociative Glucocorticoid' for DMD 3ZyGEM Teams With TATAA Biocenter To Distribute Its Innovative Nucleic acid Extraction Kits 2ZyGEM Teams With TATAA Biocenter To Distribute Its Innovative Nucleic acid Extraction Kits 3CMC Biologics Honored as Finalist for Washington's Manufacturing Company of the Year Award 2
Hybridization chamblers suitable for use with all ChIP-GLAS microarrays....
Integrins Sampler Kit 10g each...
Protein Tyrosine Phosphatase Sampler Kit 10g each...
... Solid phase reagent ... purification; Easy & unique ... Compatible with detergents and ... & recover non-envelop viruses ...
Biology Products: